

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 0 891 984 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
20.01.1999 Bulletin 1999/03

(51) Int Cl. 6: C07K 14/315, A61K 39/085,  
C07K 16/12, C12N 15/31,  
C12Q 1/68, G01N 33/50

(21) Application number: 98304786.1

(22) Date of filing: 17.06.1998

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 20.06.1997 US 879531

(71) Applicants:

• SMITHKLINE BEECHAM CORPORATION  
Philadelphia Pennsylvania 19103 (US)

• SMITHKLINE BEECHAM PLC  
Brentford, Middlesex TW8 9EP (GB)

(72) Inventor: Wallis, Nicola Gail  
Brentford, Middlesex, TW8 9EP (GB)

(74) Representative: Mallalieu, Catherine Louise et al  
D. Young & Co.,  
21 New Fetter Lane  
London EC4A 1DA (GB)

### (54) NUCLEIC ACID ENCODING STREPTOCOCCUS PNEUMONIAE RESPONSE REGULATOR

(57) The invention provides response regulator polypeptides and DNA (RNA) encoding response regulator polypeptides and methods for producing such

polypeptides by recombinant techniques. Also provided are methods for utilizing response regulator polypeptides to screen for antibacterial compounds.

**Description****FIELD OF THE INVENTION**

5 This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the response regulator family, hereinafter referred to as "response regulator".

**10 BACKGROUND OF THE INVENTION**

The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since 15 its isolation more than 100 years ago, *Streptococcus pneumoniae* has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with *S. pneumoniae*, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.

20 The frequency of *Streptococcus pneumoniae* infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Streptococcus pneumoniae* strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.

25 While certain Streptococcal factors associated with pathogenicity have been identified, e.g., capsule polysaccharides, peptidoglycans, pneumolysins, PspA Complement factor H binding component, autolysin, neuraminidase, peptide permeases, hydrogen peroxide, IgA1 protease, the list is certainly not complete. Further very little is known concerning the temporal expression of such genes during infection and disease progression in a mammalian host. Discovering the sets of genes the bacterium is likely to be expressing at the different stages of infection, particularly 30 when an infection is established, provides critical information for the screening and characterization of novel antibiotics which can interrupt pathogenesis. In addition to providing a fuller understanding of known proteins, such an approach will identify previously unrecognised targets.

35 Many two component signal transduction systems (TCSTS) have been identified in bacteria (Stock, J. B., Ninfa, A.J. & Stock, A.M. (1989) *Microbiol. Rev.* 53, 450-490). These are involved in the bacterium's ability to monitor its surroundings and adapt to changes in its environment. Several of these bacterial TCSTS are involved in virulence and bacterial pathogenesis within the host.

40 Response regulators are components of the TCSTS. These proteins are phosphorylated by histidine kinases and in turn once phosphorylated effect the response, often through a DNA binding domain becoming activated. The response regulators are characterized by a conserved N-terminal domain of approximately 100 amino acids. The N-terminal domains of response regulators as well as retaining five functionally important residues, corresponding to the 45 residues D12, D13, D57, T87, K109 in CheY (Matsumura, P., Rydel, J.J., Linzmeier, R. & Vacante, D. (1984) *J. Bacteriol.* 160, 36-41), have conserved structural features (Volz, K. (1993) *Biochemistry* 32, 11741-11753). The 3-dimensional structures of CheY from *Salmonella typhimurium* (Stock, A.M., Mottonen, J.M., Stock, J.B. & Schutt, C.E. (1989) *Nature*, 337, 745-749) and *Escherichia coli* (Volz, K. & Matsumura, P. (1991) *J. Biol. Chem.* 266, 15511-15519) and the 50 N-terminal domain of nitrogen regulatory protein C from *S. typhimurium* (Volkman, B.F., Nohale, M.J., Amy, N.K., Kustu, S. & Wemmer, D.E. (1995) *Biochemistry*, 34 1413-1424), are available, as well as the secondary structure of SpoOF from *Bacillus subtilis* (Feher, V.A., Zapf, J.W., Hoch, J.A., Dahlquist, F.W., Whiteley, J.M. & Cavanagh, J. (1995) *Protein Science*, 4, 1801-1814). These structures have a (a/b)5 fold. Several structural residues are conserved between different response regulator sequences, specifically hydrophobic residues within the  $\beta$ -sheet hydrophobic core and sites from the a-helices. This family of response regulators includes DegU protein from *Bacillus brevis*. DegU is the response regulator of the TCSTS involved in regulating the production of extracellular proteases (Henner, D.J., Yang, M. & Ferrari, E. (1988) *J. Bacteriol.* 170, 5102-5109).

55 Histidine kinases are components of the TCSTS which autophosphorylate a histidine residue. The phosphate group is then transferred to the cognate response regulator. The Histidine kinases have five short conserved amino acid sequences (Stock, J. B., Ninfa, A.J. & Stock, A.M. (1989) *Microbiol. Rev.* 53, 450-490, Swanson, R.V., Alex, L.A. & Simon, M.I. (1994) *TIBS* 19 485-491). These are the histidine residue, which is phosphorylated, followed after approximately 100 residues by a conserved asparagine residue. After another 15 to 45 residues a DXGXG motif is found, followed by a FXXF motif after another 10-20 residues. 10-20 residues further on another glycine motif, GXG is found.

The two glycine motifs are thought to be involved in nucleotide binding.

Among the processes regulated by TCSTS are production of virulence factors, motility, antibiotic resistance and cell replication. Inhibitors of TCSTS proteins would prevent the bacterium from establishing and maintaining infection of the host by preventing it from producing the necessary factors for pathogenesis and thereby have utility in anti-bacterial therapy.

Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.

The polypeptides of the invention have amino acid sequence homology to a known DegU from *Bacillus brevis* protein.

## SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides that have been identified as novel response regulator polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known amino acid sequence or sequences of other proteins such as DegU from *Bacillus brevis* protein.

It is a further object of the invention to provide polynucleotides that encode response regulator polypeptides, particularly polynucleotides that encode the polypeptide herein designated response regulator.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding response regulator polypeptides comprising the sequence set out in Table 1 [SEQ ID NO: 1] which includes a full length gene, or a variant thereof.

In another particularly preferred embodiment of the invention there is a novel response regulator protein from *Streptococcus pneumoniae* comprising the amino acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.

In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the *Streptococcus pneumoniae* 0100993 strain contained in the deposited strain.

A further aspect of the invention there are provided isolated nucleic acid molecules encoding response regulator, particularly *Streptococcus pneumoniae* response regulator, including mRNAs, cDNAs, genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of response regulator and polypeptides encoded thereby.

Another aspect of the invention there are provided novel polypeptides of *Streptococcus pneumoniae* referred to herein as response regulator as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

Among the particularly preferred embodiments of the invention are variants of response regulator polypeptide encoded by naturally occurring alleles of the response regulator gene.

In a preferred embodiment of the invention there are provided methods for producing the aforementioned response regulator polypeptides.

In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.

In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing response regulator expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation, and administering a response regulator polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a *Streptococcus pneumoniae* bacteria.

In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to response regulator polynucleotide sequences, particularly under stringent conditions.

In certain preferred embodiments of the invention there are provided antibodies against response regulator polypeptides.

In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable

of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.

5 In accordance with yet another aspect of the invention, there are provided response regulator agonists and antagonists, preferably bacteriostatic or bacteriocidal agonists and antagonists.

In a further aspect of the invention there are provided compositions comprising a response regulator polynucleotide or a response regulator polypeptide for administration to a cell or to a multicellular organism.

10 Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

## **GLOSSARY**

15 The following definitions are provided to facilitate understanding of certain terms used frequently herein.  
"Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

an exogenous polynucleotide sequence.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing. Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heijne, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM *J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO: 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated," as the term is employed herein.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single- and double-stranded

5 DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" also includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" 10 as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, 15 enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)" also embraces short polynucleotides often referred to as oligonucleotide(s).

20 "Polypeptide(s)" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide(s)" refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids. "Polypeptide(s)" include those modified either by natural processes, 25 such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains; and the amino or carboxyl termini. Modifications include, for example, acetylation, 30 acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, 35 prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, such as arginylation, and ubiquitination. See, for instance, *PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993) and Wold, F., *Posttranslational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS*, B. C. Johnson, Ed., Academic Press, New York (1983); Seifter et al., *Meth. Enzymol.* 182:626-646 (1990) and Rattan et al., *Protein Synthesis: Posttranslational Modifications and Aging*, Ann. N.Y. Acad. Sci. 663: 48-62 (1992). Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular 40 polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.

45 "Variant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

55

## DESCRIPTION OF THE INVENTION

The invention relates to novel response regulator polypeptides and polynucleotides as described in greater detail

below. In particular, the invention relates to polypeptides and polynucleotides of a novel response regulator of *Streptococcus pneumoniae*, which is related by amino acid sequence homology to DegU from *Bacillus brevis* polypeptide. The invention relates especially to response regulator having the nucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the response regulator nucleotide sequences of the 5 DNA in the deposited strain and amino acid sequences encoded thereby.

10 TABLE 1

## 15 Response regulator Polynucleotide and Polypeptide Sequences

(A) Sequences from *Streptococcus pneumoniae* response regulator polynucleotide sequence 20 [SEQ ID NO:1].

5'-1 GAAAAAGACC CTGTCACCTG AGGAGTATGC AGTTACCCAG GAAAATCAAA

25 51 CAGAACGAGC TTTCTCAAAC CGTTACTGGG ATAAATTTGA ATCCGGTATC

101 TATGTGGATA TAGCAACTGG GGAACCTCTC TTTTCATCAA AAGACAAATT

25 151 TGAGTCTGGT TGTGGCTGGC CTAGTTTAC CCAACCCATC AGTCCAGATG

201 TTGTCACCTA CAAGGAAGAT AAGTCCTACA ATATGACCGCG TATGGAAGTG

30 251 CGGAGCCGAG TAGGAGATTG TCACCTGGG CATGTCTTA CGGATGGTCC

301 ACAGGACAAG GGCGGCTTAC GTTACTGTAT CAATAGCCTC TCTATCCGCT

35 351 TTATTCCCAA AGACCAAATG GAAGAAAAAG GCTACGCTTA TTTACTAGAT

40 401 TATGTTGATT AATACTCTTC GAAAATCTCT TCAAACCACG TCAGCGTCGC

45 451 CTTACCGTAT GTAGGGTTAC TGACTCCGTC AGTTTTATCT ACAACCTCAA

501 AGCTATACTT TGAGCTGACT TCGTCAGTT TATCTACAAC CTCAAAGCGG

45 551 TACTTGAGA AACCTGTGGC TATCTTCCTA GTTTACTTT TGATTTTAT

601 TGAGTATAAG AGGTCTTC TAAAGCAGTTA GAGGAGAATT TTGCTATACT

50 651 GATACTAGTA AGTGGTAAAG GAGCAGAGCA TGACCTACAC AATCTTAATC

701 GTAGAAGATG AATATCTGGT AAGACAAGGT TTGACTAAC TGGTCAATGT

55 751 AGCAGCCTAC GATATGGAAA TCATCGGTCA GGCTGAAAAT GGAAGGCAGG

801 CTTGGGAATT GATCCAAAAG CAGGTTCCAG ATATCATTTC AACCGATATC  
 5 851 AACATGCCTC ATCTAAATGG CATCCAGTTG GCCAGTCTGG TACGAGAAAC  
 901 CTATCCTCAG GTTCATTTGG TCTTTTAAC AGGTTACGAT GATTTGATT  
 10 951 ATGCCTTGTC TGCTGTCAAAG CTAGGTGTGG ACGACTACCT GCTCAAACCC  
 1001 TTTTCTCGTC AGGATATTGA GGAAATGTTG GGGAAAATCA AACAAAAACT  
 15 1051 AGACAAGGAA GAGAAAGAAG AGCAGTTACA AGATTTATTG ACTAATAGGT  
 1101 TTGAAGGAAA CATGGCCAG AAAATCCAGT CTCATCTGGC TGATAGCCAA  
 20 1151 TTTAGTTAA AGTCTTTAGC CAGTGACTTA GGTTTAGTC CGACCTATCT  
 1201 GAGTTCCCTG ATTAAGAAAAG AGTTGGGCTT GCCTTTCAAG GATTATCTAG  
 25 1251 TGAGAGAACG TGTTAACCAA GCCAAGCTCT TGCTTTAAC TACAGATCTG  
 1301 AAGATTTATG AGATCGCAGA GAAGGTTGGT TTTGAAGATA TGAACATATT  
 30 1351 TACCCAACGT TTTAACGAGA TTGCAGGTGT GACACCTCGT CAGTTAACAG  
 1401 AGGGAGAAGA CCGATGAAGC GTTCTTCTCT TTTAGTTAGA ATGGTTATTT  
 35 1451 CCATCTTCTC GGTCTTCTC ATTCTCCTAG CTCTGGTTGG AACTTTCTAC  
 1501 TATCAATCAA GTTCTTCAGC CATTGAGGCC ACCATTGAGG GCAACAGCCA  
 40 1551 AACGACCATC AGCCAGACTA GCCACTTTAT TCAGTCTTAT ATCAAAAAAC  
 1601 TAGAAACCAC TTGACCGGT TTGACCCAGC AGACGGATGT TCTGGCCTAT  
 45 1651 GCTGAGAATC CCAGTCAAGA CAAGGTCGAG GGAATCCGAG ATTTGTTTT  
 1701 GACCATCTTG AAGTCAGATA AGGACTTGAA AACTGTTGTG CTGGTGACCA  
 50 1751 AATCTGGTCA GGTCAATTCT ACAGATGACA CTGTGCAGAT GAAAACCTTCC

1801 TCTGATATGA TGGCTGAGGA TTGGTACCAA AAGGCCATTC ATCAGGGAGT  
 5 1851 GATGCCTGTT TTGACTCCAG CTCGTAAATC AGATAGTCAG TGGGTCATT  
 1901 CTGTCACTCA AGAACTTGTT GATGCAAAGG GAGCCAATCT TGGTGTGCTT  
 10 1951 CGTTGGATA TTTCTTATGA AACTCTGGAA GCCTATCTCA ATCAACTCCA  
 2001 GTTGGGGCAG CAGGGCTTTG CCTTCATTAT CAATGAAAAC CATGAATTG  
 15 2051 TCTACCATCC TCAACACACA GTTTATAGTT CGTCTAGCAA AATGGAGGCT  
 2101 ATGAAACCCCT ACATCGAGAC AGGTCAAGGT TATACTCCTG GTCACAAATC  
 20 2151 CTACGTCAGT CAAGAGAAGA TTGCAGGAAC TGATTGGACG GTACTTGGCG  
 2201 TGTCAATCATT GGAAAAGTTA GACCAGGTTG GGAGTCAGCT CTTGTGGACC  
 25 2251 TTGCTTGGGG CCAGTGTAC ATCTCTTCTT GTCTGTCTCT GCTTAGTGTG  
 2301 GTTCAGTCTT AAACGCTGGA TTGCTCCTTT GAAGGATTG AGAGAAACCA  
 30 2351 TGTTGGAAAT TGCTTCTGGT GCTAAAATC TTCTGCCAA GGAAGTTGGT  
 2401 GCCTATGAAC TGAGAGAAGT AACTCGCCAA TTTAATGCCA TGTTGGATCA  
 35 2451 GATTGATCAG TTGATGGTAG CTATTCGTAG CCAGGGAGAA ACGACCCGTC  
 2501 AGTACCAACT TCAAGCCCTT TCGAGCCAGA TTAATCCACA TTTCCTCTAT  
 40 2551 AACACTTTGG ACACCATCAT CTGGATGGCT GAATTCATG ATAGTCAGCG  
 2601 AGTGGTGCAG GTGACCAAGT CCTTGGCAAC CTATTTCCGC TTGGCACTCA  
 45 2651 ATCAAGGCAA AGACTTGATT TGTCTCTCTG ACGAAATCAA TCATGTCCGC  
 2701 CAGTATCTCT TTATCCAGAA ACAACGCTAT GGAGATAAGC TGGAATACGA  
 50 2751 AATTAATGAA AATGTTGCCT TTGATAATTT AGTCTTACCC AAGCTGGTCC  
 2801 TACAACCCCT TGTAGAAAAT GCTCTTACCC ATGGCATTAA GGAAAAGGAA

2851 GGTCAAGGGCC ATATTAACCT TTCTGTCCAG AAACAGGATT CGGGATTGGT  
 5  
 2901 CATCCGTATT GAGGATGATG GCGTTGGCTT CCAAAATGCT GGTGATAGTA  
 10  
 2951 GTCAAAGTCA ACTCAAACGT GGGGGAGTTG GTCTTCAAAA TGTCGATCAA  
 15  
 3001 CGGCTCAAAC TTCATTTGG AGCCAATTAC CAGATGAAGA TTGATTCTAC  
 3051 ACCCCAAAAA GGGACGAAAG TTGAAATATA TATAAATACA GTAGAAACTA  
 15  
 3101 GATAACTCCC AGTCAATTCT GGGAGTCTTA TGCCT  
 -3'

20 (B) Response regulator polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:2].

NH<sub>2</sub>-1 MTYTILIVED EYLVRQGLTK LVNVAYDME IIGQAENGRQ AWELIQKQVP

25 51 DIIILTDINMP HLNGIQLASL VRETYPVHL VFLTGYDDFD YALSAVKLGV  
 101 DDYLLKPFPSR QDIEEMLGKI KQKLDKEEKE EQLQDLLTNR FEGNMAQKIQ  
 30 151 SHLADSQFSL KSLASDLGFS PTYLSSLIKK ELGLPFQDYL VRERVVKQAKL  
 201 LLLTTDLKIY EIAEKVGFED MNYFTQRFKQ IAGVTPRQFK KGEDR-COOH

35 (C) Polynucleotide sequence embodiments [SEQ ID NO:1].

40 X-(R<sub>1</sub>)<sub>n</sub>-1 GAAAAAGACC CTGTCACCTG AGGAGTATGC AGTTACCCAG GAAAATCAAA  
 51 CAGAACGAGC TTTCTCAAAC CGTTACTGGG ATAAATTGTA ATCCGGTATC  
 101 TATGTGGATA TAGCAACTGG GGAACCTCTC TTTTCATCAA AAGACAAATT  
 45 151 TGAGTCTGGT TGTGGCTGGC CTAGTTTAC CCAACCCATC AGTCCAGATG  
 201 TTGTCACCTA CAAGGAAGAT AAGTCCTACA ATATGACCGCG TATGGAAGTG  
 50 251 CGGAGCCGAG TAGGAGATTC TCACCTTGCG CATGTCTTTA CGGATGGTCC  
 301 ACAGGACAAG GGCAGCTTAC GTTACTGTAT CAATAGCCTC TCTATCCGCT

351 TTATTCCCAA AGACCAAATG GAAGAAAAAG GCTACGCTTA TTTACTAGAT  
 5  
 401 TATGTTGATT AATACTCTTC GAAAATCTCT TCAAACCACG TCAGCGTCGC  
 10  
 451 CTTACCGTAT GTAGGGTTAC TGACTCCGTC AGTTTTATCT ACAACCTCAA  
 501 AGCTATACTT TGAGCTGACT TCGTCAGTTT TATCTACAAC CTCAAAGCGG  
 15  
 551 TACTTTGAGA AACCTGTGGC TATCTTCCTA GTTTACTTTT TGATTTTTAT  
 601 TGAGTATAAG AGGTCTTC C TAAGCAGTTA GAGGAGAATT TTGCTATACT  
 20  
 651 GATACTAGTA AGTGGTAAAG GAGCAGAGCA TGACCTACAC AATCTTAATC  
 701 GTAGAAGATG AATATCTGGT AAGACAAGGT TTGACTAAC TGGTCAATGT  
 25  
 751 AGCAGCCTAC GATATGGAAA TCATCGGTCA GGCTGAAAAT GGAAGGCAGG  
 801 CTTGGGAATT GATCCAAAAG CAGGTTCCAG ATATCATTAA ACCGATATC  
 30  
 851 AACATGCCTC ATCTAAATGG CATCCAGTTG GCCAGTCTGG TACGAGAAC  
 901 CTATCCTCAG GTTCATTGG TCTTTTAAC AGGTTACGAT GATTTGATT  
 35  
 951 ATGCCTTGTC TGCTGTAAA CTAGGTGTGG ACGACTACCT GCTCAAACCC  
 1001 TTTCTCGTC AGGATATTGA GGAAATGTTG GGGAAAATCA AACAAAAACT  
 40  
 1051 AGACAAGGAA GAGAAAGAAG AGCAGTTACA AGATTATTG ACTAATAGGT  
 1101 TTGAAGGAAA CATGGCCCAG AAAATCCAGT CTCATCTGGC TGATAGCCAA  
 45  
 1151 TTTAGTTAA AGTCTTTAGC CAGTGACTTA GGTTTAGTC CGACCTATCT  
 1201 GAGTTCCCTTG ATTAAGAAAG AGTTGGGCTT GCCTTTCAAG GATTATCTAG  
 50  
 1251 TGAGAGAACG TGTTAAACAA GCCAAGCTCT TGCTTTAAC TACAGATCTG  
 1301 AAGATTATG AGATCGCAGA GAAGGTTGGT TTTGAAGATA TGAACATATT  
 55

1351 TACCCAACGT TTTAAGCAGA TTGCAGGTGT GACACCTCGT CAGTTAAGA  
 5 1401 AGGGAGAAGA CCGATGAAGC GTTCTTCTCT TTTAGTTAGA ATGGTTATTT  
 1451 CCATCTTCT GTTCTTCTC ATTCTCCTAG CTCTGGTTGG AACTTTCTAC  
 10 1501 TATCAATCAA GTTCTTCAGC CATTGAGGCC ACCATTGAGG GCAACAGCCA  
 1551 AACGACCATC AGCCAGACTA GCCACTTAT TCAGTCTTAT ATCAAAAAAAC  
 1601 TAGAAACCAC TTCGACCGGT TTGACCCAGC AGACGGATGT TCTGGCCTAT  
 1651 GCTGAGAATC CCAGTCAAGA CAAGGTCGAG GGAATCCGAG ATTTGTTTT  
 20 1701 GACCATCTTG AAGTCAGATA AGGACTTGAA AACTGTTGTG CTGGTGACCA  
 1751 AATCTGGTCA GGTCATTCT ACAGATGACA GTGTGCAGAT GAAAACTTCC  
 25 1801 TCTGATATGA TGGCTGAGGA TTGGTACCAA AAGGCCATTC ATCAGGGAGT  
 1851 GATGCCTGTT TTGACTCCAG CTCGTAAATC AGATAGTCAG TGGGTCATT  
 30 1901 CTGTCACTCA AGAACTTGTT GATGCAAAGG GAGCCAATCT TGGTGTGCTT  
 1951 CGTTGGATA TTTCTTATGA AACTCTGGAA GCCTATCTCA ATCAACTCCA  
 35 2001 GTTGGGGCAG CAGGGCTTG CCTTCATTAT CAATGAAAAC CATGAATTG  
 2051 TCTACCATCC TCAACACACA GTTTATAGTT CGTCTAGCAA AATGGAGGCT  
 40 2101 ATGAAACCCCT ACATCGAGAC AGGTCAGGGT TATACTCCTG GTCACAAATC  
 2151 CTACGTCAGT CAAGAGAAGA TTGCAGGAAC TGATTGGACG GTACTTGGCG  
 45 2201 TGTCAATCATT GGAAAAGTTA GACCAGGTTG GGAGTCAGCT CTTGTGGACC  
 2251 TTGCTTGGGG CCAGTGTAC ATCTCTTCTT GTCTGTCTCT GCTTAGTGTG  
 50 2301 GTTCAGTCTT AAACGCTGGA TTGCTCCTT GAAGGATTG AGAGAAACCA  
 2351 TGTTGGAAAT TGCTTCTGGT GCTCAAATC TTCGTGCCAA GGAAGTTGGT

2401 GCCTATGAAC TGAGAGAAGT AACTCGCCAA TTTAATGCCA TGTTGGATCA  
5

2451 GATTGATCAG TTGATGGTAG CTATTCGTAG CCAGGGAGAA ACGACCCGTC

10 2501 AGTACCAACT TCAAGCCCTT TCGAGCCAGA TTAATCCACA TTTCCTCTAT

15 2551 AACACTTTGG ACACCATCAT CTGGATGGCT GAATTCATG ATAGTCAGCG

20 2601 AGTGGTGCAG GTGACCAAGT CCTTGGCAAC CTATTTCCGC TTGGCACTCA

25 2651 ATCAAGGCAA AGACTTGATT TGTCTCTCTG ACGAAATCAA TCATGTCCGC

30 2701 CAGTATCTCT TTATCCAGAA ACAACGCTAT GGAGATAAGC TGGAATACGA

35 2751 AATTAATGAA AATGTTGCCT TTGATAATTT AGTCTTACCC AAGCTGGTCC

40 2801 TACAACCCCT TGTAGAAAAT GCTCTTACC ATGGCATTAA GGAAAAGGAA

45 2851 GGTCAAGGCC ATATTAACT TTCTGTCCAG AAACAGGATT CGGGATTGGT

50 2901 CATCCGTATT GAGGATGATG GCGTTGGCTT CCAAAATGCT GGTGATAGTA

3051 GTCAAAGTCA ACTCAAACGT GGGGGAGTTG GTCTTAAAAA TGTCGATCAA

3001 CGGCTCAAAC TTCATTTGG AGCCAATTAC CAGATGAAGA TTGATTCTAC

3051 ACCCCAAAAA GGGACGAAAG TTGAAATATA TATAAATACA GTAGAAACTA

55

3101 GATAACTCCC AGTCAATTCT GGGAGTCTTA TGCCT  
 - (R<sub>2</sub>)<sub>n</sub>-Y

5

(D) Polypeptide sequence embodiments [SEQ ID NO:2].

X-(R<sub>1</sub>)<sub>n-1</sub> MTYTILIVED EYLVRQGLTK LVNVAAAYDME IIGQAENGRQ AWELIQQKQVP

10

51 DIILTDINMP HLNGIQLASL VRETYQPQVHL VFLTGYDDFD YALSAVKLGV

101 DDYLLKPFPSR QDIEEMLGKI KQKLDKEEKE EQLQDLLTNR FEGNMAQKIQ

15

151 SHLADSQFSL KSLASDLGFS PTYLSSLIKK ELGLPFQDYL VRERVKQAKL

201 LLLTTDLKIY EIAEKVGFED MNYFTQRFKQ IAGVTPRQFK KGEDR- (R<sub>2</sub>)<sub>n</sub>-Y

20

(E) Polynucleotide sequence from *Streptococcus pneumoniae* Histidine Kinase [SEQ ID NO:3], cognate of the Response Regulator of the invention.

25

5'-1 GAAAAAAGACC CTGTCACCTG AGGAGTATGC AGTTACCCAG GAAAATCAA

30

51 CAGAACGAGC TTTCTCAAAC CGTTACTGGG ATAAATTGAA ATCCGGTATC

35

101 TATGTGGATA TAGCAACTGG GGAACCTCTC TTTTCATCAA AAGACAAATT

151 TGAGTCTGGT TGTGGCTGGC CTAGTTTAC CCAACCCATC AGTCCAGATG

40

201 TTGTCACCTA CAAGGAAGAT AAGTCCTACA ATATGACGCG TATGGAAGTG

251 CGGAGCCGAG TAGGAGATTC TCACCTTGGG CATGTCTTA CGGATGGTCC

45

301 ACAGGGACAAG GGCAGCTTAC GTTACTGTAT CAATAGCCTC TCTATCCGCT

351 TTATTCCCAA AGACCAAATG GAAGAAAAAG GCTACGCTTA TTTACTAGAT

50

401 TATGTTGATT AATACTCTTC GAAAATCTCT TCAAACCCACG TCAGCGTCGC

451 CTTACCGTAT GTAGGGTTAC TGACTCCGTC AGTTTTATCT ACAACCTCAA

55

501 AGCTATACTT TGAGCTGACT TCGTCAGTTT TATCTACAAC CTCAAAGCGG

551 TACTTTGAGA AACCTGTGGC TATCTTCCTA GTTTACTTTTG TGATTTTAT

601 TGAGTATAAG AGGTCTTCC TAAGCAGTTA GAGGAGAATT TTGCTATACT  
 5 651 GATACTAGTA AGTGGTAAAG GAGCAGAGCA TGACCTACAC AATCTTAATC  
 701 GTAGAAAGATG AATATCTGGT AAGACAAAGGT TTGACTAAAC TGGTCAATGT  
 10 751 AGCAGCCTAC GATATGGAAA TCATCGGTCA GGCTGAAAAT GGAAGGCAGG  
 801 CTTGGGAATT GATCCAAAAG CAGGTTCCAG ATATCATTTC AACCGATATC  
 15 851 AACATGCCTC ATCTAAATGG CATCCAGTTG GCCAGTCTGG TACGAGAAAC  
 901 CTATCCTCAG GTTCATTTGG TCTTTTAAC AGGTTACGAT GATTTGATT  
 20 951 ATGCCTTGTC TGCTGTCAA CTAGGTGTGG ACGACTACCT GCTCAAACCC  
 1001 TTTTCTCGTC AGGATATTGA GGAAATGTTG GGGAAAATCA AACAAAAACT  
 25 1051 AGACAAGGAA GAGAAAGAAG ACCAGTTACA AGATTATTG ACTAATAGGT  
 1101 TTGAAGGAAA CATGGCCAG AAAATCCAGT CTCATCTGGC TGATAGCCAA  
 30 1151 TTTAGTTAA AGTCTTAGC CAGTGACTTA GGTTTAGTC CGACCTATCT  
 1201 GAGTTCCCTTG ATTAAGAAAG AGTTGGCTT GCCTTTCAAG GATTATCTAG  
 35 1251 TGAGAGAACG TGTTAAACAA GCCAAGCTCT TGCTTTAAC TACAGATCTG  
 1301 AAGATTATG AGATCGCAGA GAAGGTTGGT TTTGAAGATA TGAACATATT  
 40 1351 TACCCAACGT TTTAAGCAGA TTGCAGGTGT GACACCTCGT CAGTTAAC  
 1401 AGGGAGAAGA CCGATGAAGC GTTCTCTCT TTTAGTTAGA ATGGTTATT  
 45 1451 CCATCTTCTC GGTCTTCAGC ATTCTCCTAG CTCTGGTTGG AACTTTCTAC  
 1501 TATCAATCAA GTTCTTCAGC CATTGAGGCC ACCATTGAGG GCAACAGCCA  
 50 1551 AACGACCATC AGCCAGACTA GCCACTTAT TCAGTCTTAT ATCAAAAAAC  
 1601 TAGAAACCAC TTGACCCGGT TTGACCCAGC AGACGGATGT TCTGGCCTAT  
 55

1651 GCTGAGAATC CCAGTCAAGA CAAGGTCGAG GGAATCCGAG ATTTGTTTT  
 5  
 1701 GACCATCTTG AAGTCAGATA AGGACTTGAA AACTGTTGTG CTGGTGACCA  
 10  
 1751 AATCTGGTCA GGTCATTCT ACAGATGACA GTGTGCAGAT GAAAACCTCC  
 1801 TCTGATATGA TGGCTGAGGA TTGGTACCAA AAGGCCATTC ATCAGGGAGT  
 15  
 1851 GATGCCTGTT TTGACTCCAG CTCGTAAATC AGATAGTCAG TGGGTCAATT  
 1901 CTGTCACTCA AGAACTTGTG GATGCAAAGG GAGCCAATCT TGGTGTGCTT  
 20  
 1951 CGTTTGGATA TTTCTTATGA AACTCTGGAA GCCTATCTCA ATCAACTCCA  
 2001 GTTGGGGCAG CAGGGCTTG CCTTCATTAT CAATGAAAAC CATGAATTG  
 25  
 2051 TCTACCATCC TCAACACACA GTTTATAGTT CGTCTAGCAA AATGGAGGCT  
 2101 ATGAAACCCCT ACATCGAGAC AGGTCAAGGT TATACTCCTG GTCACAAATC  
 30  
 2151 CTACGTCAGT CAAGAGAAGA TTGCAGGAAC TGATTGGACG GTACTTGGCG  
 2201 TGTCATCATT GGAAAAGTTA GACCAGGTTC GGAGTCAGCT CTTGTGGACC  
 35  
 2251 TTGCTTGGGG CCAGTGTAC ATCTCTTCTT GTCTGTCTCT GCTTAGTGTG  
 2301 GTTCAGTCTT AACCGCTGGA TTGCTCCTT GAAGGATTG AGAGAAACCA  
 40  
 2351 TGTTGGAAAT TGCTTCTGGT GCTAAAATC TTCGTGCCAA GGAAGTTGGT  
 2401 GCCTATGAAC TGAGAGAAGT AACTCGCCAA TTTAATGCCA TGTTGGATCA  
 45  
 2451 GATTGATCAG TTGATGGTAG CTATTCGTAG CCAGGGAGAA ACGACCCGTC  
 2501 AGTACCAACT TCAAGCCCTT TCGAGCCAGA TTAATCCACA TTTCCTCTAT  
 50  
 2551 AACACTTTGG ACACCATCAT CTGGATGGCT GAATTCATG ATAGTCAGCG  
 2601 AGTGGTGCAG GTGACCAAGT CCTIGGCAAC CTATTTCCGC TTGGCACTCA

2651 ATCAAGGCAA AGACTTGATT TGTCTCTCTG ACGAAATCAA TCATGTCCGC  
 5 2701 CAGTATCTCT TTATCCAGAA ACAACGCTAT GGAGATAAGC TGGAATAACGA  
 2751 AATTAATGAA AATGTTGCCT TTGATAATTT AGTCTTACCC AAGCTGGTCC  
 10 2801 TACAACCCCT TGTAGAAAAT GCTCTTACC ATGGCATTAA GGAAAAGGAA  
 2851 GGTCAGGGCC ATATTAAACT TTCTGTCCAG AAACAGGATT CGGGATTGGT  
 15 2901 CATCCGTATT GAGGATGATG GCCTTGGCTT CCAAAATGCT GGTGATAGTA  
 2951 GTCAAAGTCA ACTCAAACGT GGGGAGTTG GTCTTCAAAA TGTCGATCAA  
 20 3001 CGGCTCAAAC TTCATTTGG AGCCAATTAC CAGATGAAGA TTGATTCTAC  
 3051 ACCCCAAAAA GGGACGAAAG TTGAAATATA TATAAATACA GTAGAAACTA  
 25 3101 GATAACTCCC AGTCAATTCT GGGAGTCTTA TGCCT  
 -3'

30 (F) Polypeptide sequences from *Streptococcus pneumoniae* Histidine Kinase [SEQ ID NO:4] deduced from the polynucleotide of SEQ ID NO:3, cognate of the Response Regulator of the invention.

35 NH2- 1 MVISIFLVFL ILLALVGTFY YQSSSSAIEA TIEGNSQTTI SQTSHFIQSY  
 51 IKKLETTSTG LTQQTDVLAY AENPSQDKVE GIRDLFLTIL KSDKDLKTVV  
 40 101 LVTKSGQVIS TDDSVQMKTS SDMMAEDWYQ KAIHQGVMPV LTPARKSDSQ  
 151 WVISVTQELV DAKGANLGVL RLDISYETLE AYLNQLQLGQ QGFAFIINEN  
 45 201 HEFVYHPQHT VYSSSSKMEA MKPYIETGQG YTPGHKSYVS QEKIAGTDWT  
 251 VLGVSSLEKL DQVRSQLLWT LLGASVTSLL VCLCLVWFSL KRWIAPLKDL  
 50 301 RETMLEIASG AQNLRAKEVG AYELREVTRQ FNAMLDQIDQ LMVAIRSQGE  
 351 TTRQYQLQAL SSQINPHFLY NTLDTIIWMA EFHDSQRVVQ VTKSLATYFR

401 LALNQGKD LI CLSDEINHVR QYLFIQKQRY GDKLEYEINE NVAFDNLVLP  
 5  
 451 KLVLQPLVEN ALYHGIKEKE GQGHIKLSVQ KQDSGLVIRI EDDGVGFQNA  
 10  
 501 GDSSSQLKR GGVGLQNV DQ RLKLHFGANY QMKIDSTPQK GTKVEIYINT  
 551 VETR -COOH

---

15 **Deposited materials**

A deposit containing a *Streptococcus pneumoniae* 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland on 11 April 1996 and assigned deposit number 40794. The deposit was described as *Streptococcus pneumoniae* 0100993 on deposit. On 17 April 1996 a *Streptococcus pneumoniae* 0100993 DNA library in E. coli was similarly deposited with the NCIMB and assigned deposit number 40800. The *Streptococcus pneumoniae* strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains the full length response regulator gene. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

A license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.

35 **Polypeptides**

The polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO:2] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of response regulator, and also those which have at least 70% identity to the polypeptide of Table 1 [SEQ ID NO:2] or the relevant portion, preferably at least 80% identity to the polypeptide of Table 1 [SEQ ID NO:2], and more preferably at least 90% similarity (more preferably at least 90% identity) to the polypeptide of Table 1 [SEQ ID NO:2] and still more preferably at least 95% similarity (still more preferably at least 95% identity) to the polypeptide of Table 1 [SEQ ID NO:2] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

The invention also includes polypeptides of the formula set forth in Table 1 (D) wherein, at the amino terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R<sub>1</sub> and R<sub>2</sub> is any amino acid residue, and n is an integer between 1 and 1000. Any stretch of amino acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

A fragment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides. As with response regulator polypeptides fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of the amino acid sequence of Table 1 [SEQ ID NO:2], or of variants thereof, such as a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a *Streptococcus pneumoniae*, are also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-

forming regions, substrate binding region, and high antigenic index regions.

Also preferred are biologically active fragments which are those fragments that mediate activities of response regulator, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of *Streptococcus pneumoniae* or the ability to initiate, or maintain cause disease in an individual, particularly a human.

Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention.

10

### Polynucleotides

Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the response regulator polypeptide having the deduced amino acid sequence of Table 1 [SEQ ID NO:2] and polynucleotides closely related thereto and variants thereof.

Using the information provided herein, such as the polynucleotide sequence set out in Table 1 [SEQ ID NO:1], a polynucleotide of the invention encoding response regulator polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Streptococcus pneumoniae* 0100993 cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as the sequence given in Table 1 [SEQ ID NO:1], typically a library of clones of chromosomal DNA of *Streptococcus pneumoniae* 0100993 in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent conditions. By sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Illustrative of the invention, the polynucleotide set out in Table 1 [SEQ ID NO:1] was discovered in a DNA library derived from *Streptococcus pneumoniae* 0100993.

The DNA sequence set out in Table 1 [SEQ ID NO:1] contains an open reading frame encoding a protein having about the number of amino acid residues set forth in Table 1 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known in the art. The polynucleotide of SEQ ID NO: 1, between nucleotide number 680 through number 1414 encodes the polypeptide of SEQ ID NO:2. The stop codon begins at nucleotide number 1415 of SEQ ID NO:1.

The response regulator of the invention is structurally related to other proteins of the response regulator family, as shown by the results of sequencing the DNA encoding response regulator of the deposited strain. The protein exhibits greatest homology to DegU from *Bacillus brevis* protein among known proteins. The response regulator of Table 1 [SEQ ID NO:2] has about 25% identity over its entire length and about 53% similarity over its entire length with the amino acid sequence of DegU from *Bacillus brevis* polypeptide (swissprot database accession number P45662, see also, Louw, M.E., Reid, S.J., James, M.D. & Watson T.G., *Appl Microbiol.*; *Biotechnol.*, (1994) 42, 78-84).

The invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO:1]. Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence. The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA tag (Wilson et al., *Cell* 37: 767 (1984). Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

55 A preferred embodiment of the invention is the polynucleotide of comprising nucleotide 680 to 1414 set forth in SEQ ID NO:1 of Table 1 which encodes the response regulator polypeptide.

The invention also includes polynucleotides of the formula set forth in Table 1 (C) wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R<sub>1</sub> and R<sub>2</sub> is any nucleic acid

residue, and n is an integer between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

5 The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Streptococcus pneumoniae* response regulator having the amino acid sequence set out in Table 1 [SEQ ID NO:2]. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.

10 The invention further relates to variants of the polynucleotides described herein that encode for variants of the polypeptide having the deduced amino acid sequence of Table 1 [SEQ ID NO:2]. Variants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.

15 Further particularly preferred embodiments are polynucleotides encoding response regulator variants, that have the amino acid sequence of response regulator polypeptide of Table 1 [SEQ ID NO:2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of response regulator.

20 Further preferred embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding response regulator polypeptide having the amino acid sequence set out in Table 1 [SEQ ID NO:2], and polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide encoding response regulator polypeptide of the deposited strain and polynucleotides complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

25 Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO:1].

30 The invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. An example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein.

35 The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO: 1 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1 or a fragment thereof; and isolating said DNA sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein.

40 As discussed additionally herein regarding polynucleotide assays of the invention, for instance, polynucleotides of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding response regulator and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the response regulator gene. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred probes will have at least 30 bases and will have 50 bases or less.

45 For example, the coding region of the response regulator gene may be isolated by screening using the DNA sequence provided in SEQ ID NO: 1 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

50 The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays.

55 Polynucleotides of the invention that are oligonucleotides derived from the sequences of SEQ ID NOS: 1 and/or 2 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such

sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a proproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

#### **Vectors, host cells, expression**

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, enterococci *E. coli*, streptomycetes and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, (supra).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.

#### **Diagnostic Assays**

This invention is also related to the use of the response regulator polynucleotides of the invention, for use as diagnostic reagents. Detection of response regulator in a eukaryote, particularly a mammal, and especially a human,

will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with an organism comprising the response regulator gene may be detected at the nucleic acid level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique prior to analysis. RNA or cDNA may also be used in the same ways. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing amplified DNA to labeled response regulator polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA or cDNA may also be used for the same purpose, PCR or RT-PCR. As an example, PCR primers complementary to a nucleic acid encoding response regulator can be used to identify and analyze mutations. Examples of representative primers are shown below in Table 2.

Table 2

## Primers for amplification of response regulator polynucleotides

<u>SEQ ID NO</u>	<u>PRIMER SEQUENCE</u>
------------------	------------------------

5	5'-ATGACCTACACAATCTTAATCGTAG-3'
6	5'-TCGGTCTTCTCCCTTAACTG-3'

The invention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying response regulator DNA isolated from a sample derived from an individual. The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to various techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections by *Streptococcus pneumoniae*, and most preferably otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, comprising determining from a sample derived from an individual a increased level of expression of polynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increased or decreased expression of response regulator polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of response regulator protein compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a response regulator protein, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

#### Antibodies

The polypeptides of the invention or variants thereof, or cells expressing them can be used as an immunogen to

produce antibodies immunospecific for such polypeptides. "Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeric, single chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunoglobulin expression library.

5 Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-bearing fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

10 Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

15 Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-response regulator or from naive libraries (McCafferty, J. *et al.*, (1990), *Nature* 348, 552-554; Marks, J. *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. *et al.*, (1991) *Nature* 352, 624-628).

20 If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies.

25 The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides to purify the polypeptides by affinity chromatography.

Thus, among others, antibodies against response regulator- polypeptide may be employed to treat infections, particularly bacterial infections and especially otitis media, conjunctivitis, pneumonia, bacteraemia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

30 Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.

35 The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

40 Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized"; where the complementarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones, P. *et al.* (1986), *Nature* 321, 522-525 or Tempest *et al.*, (1991) *Biotechnology* 9, 266-273.

45 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff *et al.*, *Hum Mol Genet* 1992, 1:363, Manthorpe *et al.*, *Hum. Gene Ther.* 1963:4, 419), delivery of DNA complexed with specific protein carriers (Wu *et al.*, *J Biol Chem.* 1989: 264, 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, 1986:83, 9551), encapsulation of DNA in various forms of liposomes (Kaneda *et al.*, *Science* 1989:243, 375), particle bombardment (Tang *et al.*, *Nature* 1992, 356:152, Eisenbraun *et al.*, *DNA Cell Biol* 1993, 12:791) and *in vivo* infection using cloned retroviral vectors (Seeger *et al.*, *PNAS USA* 1984:81, 5849).

#### 50 **Antagonists and agonists - assays and molecules**

55 Polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of response regulator polypeptides or polynucleotides, particularly those compounds that are

bacteriostatic and/or bacteriocidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising response regulator polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a response regulator agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the response regulator polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, *i.e.*, without inducing the effects of response regulator polypeptide are most likely to be good antagonists. Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in response regulator polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for response regulator antagonists is a competitive assay that combines response regulator and a potential antagonist with response regulator-binding molecules, recombinant response regulator binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. The response regulator can be labeled, such as by radioactivity or a colorimetric compound, such that the number of response regulator molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing response regulator-induced activities, thereby preventing the action of response regulator by excluding response regulator from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of response regulator.

Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block response regulator protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine *et al.*, *Infect. Immun.* 60:2211 (1992); to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial response regulator proteins that mediate tissue damage and; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

This invention provides a method of screening drugs to identify those which

45 i) interfere with the interaction of the response regulator with a histidine kinase, the method comprising incubating the response regulator with histidine kinase in the presence of the drug and measuring the ability of the drug to block this interaction;

50 ii) interfere with the ability of the response regulator to catalyse the transfer of phosphate group from the histidine kinase to itself, the method comprising incubating the response regulator with drug and measuring the ability of the response regulator to catalyse the removal of phosphate from phosphorylated histidine kinase; and/or

55 iii) interfere with the ability of the molecule to autodephosphorylate itself once the phosphate had been transferred, the method comprising incubating the phosphorylated response regulator with drug and measuring the ability of the response regulator to catalyse the autodephosphorylation.

55 The histidine kinase is preferably the cognate histidine kinase of the response regulator, or another histidine kinase which is capable of acting as a substrate for the response regulator, and may be from *Streptococcus pneumoniae* or another microorganism *e.g.* *Bacillus*. Polypeptide and polynucleotide sequences of the cognate kinase of the Response

Regulator of the invention are set forth in Table 1(E and F). This novel histidine kinase shows 23% identity to the YEHU protein from *Escherichia coli*.

The antagonists and agonists of the invention may be employed, for instance, to inhibit and treat otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

### Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with response regulator, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Streptococcus pneumoniae* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of response regulator, or a fragment or a variant thereof, for expressing response regulator, or a fragment or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.

Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.

A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a response regulator or protein coded therefrom, wherein the composition comprises a recombinant response regulator or protein coded therefrom comprising DNA which codes for and expresses an antigen of said response regulator or protein coded therefrom. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

A response regulator polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Hemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. *Science* 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with *Streptococcus pneumoniae* will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Streptococcus pneumoniae* infection, in mammals, particularly humans.

The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused, e.g. by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intra-dermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for

enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

While the invention has been described with reference to certain response regulator protein, it is to be understood that this covers fragments of the naturally occurring protein and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.

#### 5 Compositions, kits and administration

The invention also relates to compositions comprising the polynucleotide or the polypeptides discussed above or 10 their agonists or antagonists. The polypeptides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, 15 but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

20 Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

25 The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, 30 for example as a sterile aqueous dispersion, preferably isotonic.

35 Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 40 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active 45 agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

50 In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.

55 The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the in-body time of the device. In addition, the composition could also be used to broaden perioperative cover for any surgical technique to prevent bacterial wound infections, especially *Streptococcus pneumoniae* wound infections.

Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteraemia. Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound 60 treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of 1 µg/ml to 10 mg/ml for bathing of wounds or indwelling devices.

65 A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable

individuals.

Each reference disclosed herein is incorporated by reference herein in its entirety. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety.

## 5 EXAMPLES

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

### 10 Example 1 Strain selection, Library Production and Sequencing

The polynucleotide having the DNA sequence given in SEQ ID NO:1 was obtained from a library of clones of chromosomal DNA of *Streptococcus pneumoniae* in *E. coli*. The sequencing data from two or more clones containing overlapping *Streptococcus pneumoniae* DNAs was used to construct the contiguous DNA sequence in SEQ ID NO:

15 1. Libraries may be prepared by routine methods, for example:

Methods 1 and 2 below.

Total cellular DNA is isolated from *Streptococcus pneumoniae* 0100993 according to standard procedures and size-fractionated by either of two methods.

#### 20 Method 1

Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures. DNA fragments of up to 11kbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added: Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and *E. coli* infected with the packaged library. The library is amplified by standard procedures.

#### Method 2

30 Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning into library vectors (e.g., RsaI, PstI, AluI, Bsh1235I), and such fragments are size-fractionated according to standard procedures. EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and *E. coli* infected with the packaged library. The library is amplified by standard procedures.

35

40

45

50

55

Annex to the description

5

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

10 (i) APPLICANT: SmithKline Beecham Corporation & SmithKline  
Beecham Plc

15 (ii) TITLE OF THE INVENTION: NOVEL RESPONSE REGULATOR

(iii) NUMBER OF SEQUENCES: 6

20 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SmithKline Beecham, Corporate Intellectual  
Property

25 (B) STREET: Two New Horizons Court

(C) CITY: Brentford

(D) STATE: Middlesex

(E) COUNTRY: United Kingdom

30 (F) ZIP: TW8 9EP

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

35 (B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

(D) SOFTWARE: FastSEQ for Windows Version 2.0

40 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

45 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

50 (B) FILING DATE:

## (viii) ATTORNEY/AGENT INFORMATION:

5 (A) NAME: CONNELL, Anthony Christopher  
(B) REGISTRATION NUMBER: 5630 & 26758  
(C) REFERENCE/DOCKET NUMBER: GM10018

## 10 (ix) TELECOMMUNICATION INFORMATION:

15 (A) TELEPHONE: + 44 1279 644 395  
(B) TELEFAX: + 44 181 975 6294  
(C) TELEX:

15

## (2) INFORMATION FOR SEQ ID NO:1:

## 20 (i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 3135 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

## 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

30

60 GAAAAAGACC CTGTCACCTG AGGAGTATGC AGTTACCCAG GAAAATCAAA CAGAACGAGC

55 TTTCTCAAAC CGTTACTGGG ATAAATTTGA ATCCGGTATC TATGTGGATA TAGCAACTGG

120 180 GGAACCTCTC TTTCATCAA AAGACAAATT TGAGTCTGGT TGTGGCTGGC CTAGTTTAC

240 300 CCAACCCATC AGTCCAGATG TTGTCACCTA CAAGGAAGAT AAGTCCTACA ATATGACGCG

360 360 TATGCAAGTG CGGAGCCGAG TAGGAGATT TCACCTTGGG CATGTCTTA CGGATGGTCC

420 420 ACAGGACAAG GGCGGCTTAC GTTACTGTAT CAATAGCCTC TCTATCCGCT TTATTCCCAA

480 480 AGACCAAATG GAAAGAAAAAG GCTACGCTTA TTTACTAGAT TATGTTGATT AATACTCTTC

540 540 GAAAATCTCT TCAAACCACG TCAGCGTCGC CTTACCGTAT GTAGGGTTAC TGACTCCGTC

55 55 AGTTTTATCT ACAACCTCAA AGCTATACTT TGAGCTGACT TCGTCAGTTT TATCTACAAC

CTCAAAGCGG TACTTGAGA AACCTGTGGC TATCTTCCTA GTTTACTTT TGATTTTAT  
 600  
 5 TGAGTATAAG AGGTCTTCC TAAGCAGTTA GAGGAGAATT TTGCTATACT GATACTAGTA  
 660  
 AGTGGTAAAG GAGCAGAGCA TGACCTACAC AATCTTAATC GTAGAAGATG AATATCTGGT  
 720  
 10 AAGACAAGGT TTGACTAAC TGGTCAATGT AGCAGCCTAC GATATGGAAA TCATCGGTCA  
 780  
 GGCTGAAAAT GGAAGGCAGG CTTGGGAATT GATCCAAAAG CAGGTTCCAG ATATCATT  
 840  
 15 AACCGATATC AACATGCCTC ATCTAAATGG CATCCAGTTG GCCAGTCTGG TACGAGAAC  
 900  
 CTATCCTCAG GTTCATTG TCTTTAAC AGGTTACGAT GATTTGATT ATGCCTTGTC  
 960  
 20 TGCTGTCAAA CTAGGTGTGG ACGACTACCT GCTCAAACCC TTTCTCGTC AGGATATTGA  
 1020  
 GGAAATGTTG GGGAAAATCA AACAAAAACT AGACAAGGAA GAGAAAGAAG AGCAGTTACA  
 1080  
 25 AGATTTATTG ACTAATAGGT TTGAAGGAAA CATGGCCAG AAAATCCAGT CTCATCTGGC  
 1140  
 TGATAGCCAA TTTAGTTAA AGTCTTAGC CAGTGACTTA GGTTTAGTC CGACCTATCT  
 1200  
 30 GAGTTCCCTG ATTAAGAAAG AGTTGGCTT GCCTTTCAAG GATTATCTAG TGAGAGAACG  
 1260  
 TGTTAAACAA GCCAAGCTCT TGCTTTAAC TACAGATCTG AAGATTATG AGATCGCAGA  
 1320  
 35 GAAGGTTGGT TTTGAAGATA TGAACATTAC TACCCAACGT TTTAAGCAGA TTGCAGGTGT  
 1380  
 GACACCTCGT CAGTTAACAGA AGGGAGAAGA CCGATGAAGC GTTCTCTCT TTTAGTTAGA  
 40 1440  
 ATGGTTATTT CCATCTTCT GGTCTTCTC ATTCTCCTAG CTCTGGTTGG AACTTTCTAC  
 1500  
 45 TATCAATCAA GTTCTTCAGC CATTGAGGCC ACCATTGAGG GCAACAGCCA AACGACCAC  
 1560  
 AGCCAGACTA GCCACTTAT TCAGTCTTAT ATCAAAAAAC TAGAAACCAC TTGACCGGT  
 1620  
 50 TTGACCCAGC AGACGGATGT TCTGGCCTAT GCTGAGAATC CCAGTCAAGA CAAGGTCGAG  
 1680  
 GGAATCCSAG ATTTGTTTT GACCATCTG AAGTCAGATA AGGACTTGAA AACTGTTGTG  
 1740  
 55

CTGGTGACCA AATCTGGTCA GGTCATTCT ACAGATGACA GTGTGCAGAT GAAAACCTCC  
 1800  
 5 TCTGATATGA TGGCTGAGGA TTGGTACCAA AAGGCCATTG ATCAGGGAGT GATGCCTGTT  
 1860  
 TTGACTCCAG CTCGTAAATC AGATAGTCAG TGGTCATTG CTGTCACTCA AGAACTTGTT  
 1920  
 10 GATGCAAAGG GAGCCAATCT TGGTGTGCTT CGTTGGATA TTTCTTATGA AACTCTGGAA  
 1980  
 GCCTATCTCA ATCAACTCCA GTTGGGCAG CAGGGCTTG CCTTCATTAT CAATGAAAAC  
 2040  
 15 CATGAATTTG TCTACCATCC TCAACACACA GTTTATAGTT CGTCTAGCAA AATGGAGGCT  
 2100  
 ATGAAACCCCT ACATCGAGAC AGGTCAGGGT TATACTCCTG GTCACAAATC CTACGTCAGT  
 2160  
 20 CAAGAGAAGA TTGCAGGAAC TGATTGGACG GTACTTGGCG TGTCATCATT GGAAAAGTTA  
 2220  
 GACCAGGTTTC GGAGTCAGCT CTTGTGGACC TTGCTTGGGG CCAGTGTAC ATCTCTTCTT  
 2280  
 25 GTCTGTCTCT GCTTAGTGTG GTTCAGTCTT AAACGCTGGA TTGCTCCTTT GAAGGATTTG  
 2340  
 AGAGAAACCA TGTTGGAAAT TGCTTCTGGT GCTCAAAATC TTCTGCCAA GGAAGTTGGT  
 30 2400  
 GCCTATGAAC TGAGAGAAGT AACTCGCCAA TTTAATGCCA TGTTGGATCA GATTGATCAG  
 2460  
 35 TTGATGGTAG CTATTCGTAG CCAGGGAGAA ACGACCCGTC AGTACCAAATC TCAAGCCCTT  
 2520  
 TCGAGCCAGA TTAATCCACA TTTCCTCTAT AACACTTGG ACACCATCAT CTGGATGGCT  
 2580  
 40 GAATTTCATG ATAGTCAGCG AGTGGTGCAG GTGACCAAGT CCTTGGCAAC CTATTCGCC  
 2640  
 TTGGCACTCA ATCAAGGCAA AGACTTGATT TGTCTCTCTG ACGAAATCAA TCATGTCCGC  
 2700  
 45 CAGTATCTCT TTATCCAGAA ACAACGCTAT GGAGATAAGC TGGAATACGA AATTAATGAA  
 2760  
 AATGTTGCCT TTGATAATTT AGTCTTACCC AAGCTGGTCC TACAACCCCT TGTAGAAAAT  
 2820  
 50 GCTCTTTACC ATGGCATTAA GGAAAAGGAA GGTCAGGGCC ATATTAAACT TTCTGTCCAG  
 2880  
 AACACAGGATT CGGGATTGGT CATCCGTATT GAGGATGATG GCGTTGGCTT CCAAAATGCT  
 2940

GGTGATAGTA GTCAAAGTCA ACTCAAACGT GGGGGAGTTG GTCTCAAAA TGTCGATCAA  
 3000  
 5 CGGCTCAAAC TTCATTTGG AGCCAATTAC CAGATGAAGA TTGATTCTAC ACCCCAAAAA  
 3060  
 GGGACGAAAG TTGAAATATA TATAAATACA GTAGAAACTA GATAACTCCC AGTCAATTCT  
 3120  
 10 GGGAGTCTTA TGCCT  
 3135

15 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 245 amino acids  
 20 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Thr Tyr Thr Ile Leu Ile Val Glu Asp Glu Tyr Leu Val Arg Gln  
 30 1 5 10 15  
 Gly Leu Thr Lys Leu Val Asn Val Ala Ala Tyr Asp Met Glu Ile Ile  
 20 25 30  
 Gly Gln Ala Glu Asn Gly Arg Gln Ala Trp Glu Leu Ile Gln Lys Gln  
 35 35 40 45  
 Val Pro Asp Ile Ile Leu Thr Asp Ile Asn Met Pro His Leu Asn Gly  
 50 55 60  
 Ile Gln Leu Ala Ser Leu Val Arg Glu Thr Tyr Pro Gln Val His Leu  
 40 65 70 75 80  
 Val Phe Leu Thr Gly Tyr Asp Asp Phe Asp Tyr Ala Leu Ser Ala Val  
 85 90 95  
 45 Lys Leu Gly Val Asp Asp Tyr Leu Leu Lys Pro Phe Ser Arg Gln Asp  
 100 105 110  
 Ile Glu Glu Met Leu Gly Lys Ile Lys Gln Lys Leu Asp Lys Glu Glu  
 115 120 125  
 50 Lys Glu Glu Gln Leu Gln Asp Leu Leu Thr Asn Arg Phe Glu Gly Asn  
 130 135 140  
 Met Ala Gln Lys Ile Gln Ser His Leu Ala Asp Ser Gln Phe Ser Leu  
 145 150 155 160  
 55

Lys Ser Leu Ala Ser Asp Leu Gly Phe Ser Pro Thr Tyr Leu Ser Ser  
 165 170 175  
 5 Leu Ile Lys Lys Glu Leu Gly Leu Pro Phe Gln Asp Tyr Leu Val Arg  
 180 185 190  
 Glu Arg Val Lys Gln Ala Lys Leu Leu Leu Thr Thr Asp Leu Lys  
 195 200 205  
 10 Ile Tyr Glu Ile Ala Glu Lys Val Gly Phe Glu Asp Met Asn Tyr Phe  
 210 215 220  
 Thr Gln Arg Phe Lys Gln Ile Ala Gly Val Thr Pro Arg Gln Phe Lys  
 225 230 235 240  
 15 Lys Gly Glu Asp Arg  
 245

20 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 3135 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

35 GAAAAAGACC CTGTCACCTG AGGAGTATGC AGTTACCCAG GAAAATCAAA CAGAACGAGC  
 60 TTTCTCAAAC CGTTACTGGG ATAAATTGATC ATCCGGTATC TATGTGGATA TAGCAACTGG  
 120 GGAACCTCTC TTTCATCAA AAGACAAATT TGAGTCTGGT TGTGGCTGGC CTAGTTTAC  
 40 180 CCAACCCATC AGTCCAGATG TTGTCACCTA CAAGGAAGAT AAGTCCTACA ATATGACGCG  
 240 TATGGAAGTG CGGAGCCGAG TAGGAGATTG TCACCTTGGG CATGTCTTA CGGATGGTCC  
 45 300 ACACGGACAAG GGCGGCTTAC GTTACTGTAT CAATAGCCTC TCTATCCGCT TTATTCCAA  
 360 320 AGACCAAATG GAAGAAAAAG GCTACGCTTA TTTACTAGAT TATGTTGATT AATACTCTTC  
 420 380 GAAAATCTCT TCAAACCACG TCAGCGTCGC CTTACCGTAT GTAGGGTTAC TGACTCCGTC  
 480 440

AGTTTATCT ACAACCTCAA AGCTATACTT TGAGCTGACT TCGTCAGTTT TATCTACAAC  
 540  
 5 CTCAAAGCGG TACTTGAGA AACCTGTGGC TATCTTCCTA GTTTACTTTT TGATTTTAT  
 600  
 TGAGTATAAG AGGTCTTCC TAAGCAGTTA GAGGAGAATT TTGCTATACT GATACTAGTA  
 660  
 10 AGTGGTAAAG GAGCAGAGCA TGACCTACAC AATCTTAATC GTAGAAGATG AATATCTGGT  
 720  
 AAGACAAGGT TTGACTAAAC TGGTCAATGT AGCAGCCTAC GATATGGAAA TCATCGGTCA  
 780  
 15 GGCTGAAAAT GGAAGGCAGG CTTGGGAATT GATCCAAAAG CAGGTTCCAG ATATCATTTC  
 840  
 AACCGATATC AACATGCCTC ATCTAAATGG CATCCAGTTG GCCAGTCTGG TACGAGAAC  
 900  
 20 CTATCCTCAG GTTCATTTGG TCTTTTAAC AGGTTACGAT GATTTGATT ATGCCTTGTC  
 960  
 TGCTGTCAA CTAGGTGTGG ACGACTACCT GCTCAAACCC TTTTCTCGTC AGGATATTGA  
 1020  
 25 GGAAATGTTG GGGAAAATCA AACAAAAACT AGACAAGGAA GAGAAAGAAG AGCAGTTACA  
 1080  
 AGATTTATTG ACTAATAGGT TTGAAGGAAA CATGGCCAG AAAATCCAGT CTCATCTGGC  
 1140  
 30 TGATAGCCAA TTTAGTTAA AGTCTTAGC CAGTGACTTA GGTTTAGTC CGACCTATCT  
 1200  
 GAGTTCCCTG ATTAAGAAAG AGTTGGCCTT GCCTTTCAAG GATTATCTAG TGAGAGAACG  
 1260  
 35 TGTTAACCAA GCCAAGCTCT TGCTTTAAC TACAGATCTG AAGATTTATG AGATCGCAGA  
 1320  
 GAAGGTTGGT TTTGAAGATA TGAACTATTT TACCCAACGT TTTAAGCAGA TTGCAGGTGT  
 1380  
 40 GACACCTCGT CAGTTAACAGA AGGGAGAAGA CCGATGAAGC GTTCTCTCT TTTAGTTAGA  
 1440  
 45 ATGGTTATTT CCATCTTCT GGTCTTCTC ATTCTCCTAG CTCTGGTTGG AACTTCTAC  
 1500  
 TATCAATCAA GTTCTTCAGC CATTGAGGCC ACCATTGAGG GCAACAGCCA AACGACCATC  
 1560  
 50 AGCCAGACTA GCCACTTAT TCAGTCTTAT ATCAAAAAAC TAGAAACCAC TTGACCCGGT  
 1620  
 TTGACCCAGC AGACGGATGT TCTGGCCTAT GCTGAGAATC CCAGTCAAGA CAAGGTCGAG  
 1680  
 55

GGAATCCGAG ATTTGTTTT GACCATCTG AAGTCAGATA AGGACTTGAA AACTGTTGTG  
 1740  
 5 CTGGTGACCA AATCTGGTCA GGTCATTTCT ACAGATGACA GTGTGCAGAT GAAAACCTCC  
 1800  
 TCTGATATGA TGGCTGAGGA TTGGTACCAA AAGGCCATTC ATCAGGGAGT GATGCCTGTT  
 1860  
 10 TTGACTCCAG CTCGTAAATC AGATAGTCAG TGGGTCAATT CTGTCACTCA AGAACTTGTG  
 1920  
 GATGCAAAGG GAGCCAATCT TGGTGTGCTT CGTTTGGATA TTTCTTATGA AACTCTGGAA  
 1980  
 15 GCCTATCTCA ATCAACTCCA GTTGGGCAG CAGGGCTTTG CCTTCATTAT CAATGAAAAC  
 2040  
 CATGAATTTG TCTACCATCC TCAACACACA GTTTATAGTT CGTCTAGCAA AATGGAGGCT  
 2100  
 20 ATGAAACCT ACATCGAGAC AGGTCAGGGT TATACTCCTG GTCACAAATC CTACGTCAGT  
 2160  
 CAAGAGAAGA TTGCAGGAAC TGATTGGACG GTACTTGGCG TGTCATCATT GGAAAAGTTA  
 2220  
 25 GACCAGGTTTC GGAGTCAGCT CTTGTGGACC TTGCTTGGGG CCAGTGTAC ATCTCTTCTT  
 2280  
 GTCTGTCCT GCTTAGTGTG GTTCAGTCTT AAACGCTGGA TTGCTCCTTT GAAGGATTG  
 2340  
 30 30 AGAGAAACCA TGTTGGAAAT TGCTTCTGGT GCTCAAAATC TTCGTGCCAA GGAAGTTGGT  
 2400  
 GCCTATGAAC TGAGAGAAGT AACTCGCCAA TTTAATGCCA TGTTGGATCA GATTGATCAG  
 2460  
 35 TTGATGGTAG CTATTCGTAG CCAGGGAGAA ACGACCCGTC AGTACCAACT TCAAGCCCTT  
 2520  
 TCGAGCCAGA TTAATCCACA TTTCTCTAT AACACTTG ACACCATCAT CTGGATGGCT  
 2580  
 40 GAATTTCATG ATAGTCAGCG AGTGGTGCAG GTGACCAAGT CCTTGGCAAC CTATTTCCGC  
 2640  
 TTGGCACTCA ATCAAGGCAA AGACTTGATT TGTCTCTCTG ACGAAATCAA TCATGTCCGC  
 2700  
 45 CAGTATCTCT TTATCCAGAA ACAACGCTAT GGAGATAAGC TGGAATACGA AATTAATGAA  
 2760  
 50 AATGTTGCCT TTGATAATT AGTCTTACCC AAGCTCGTCC TACAACCCCT TGTAGAAAAT  
 2820  
 GCTCTTACCA ATGGCATTAA GGAAAAGGAA GGTCAAGGGCC ATATTAACCT TTCTGTCCAG  
 2880  
 55

AAACAGGATT CGGGATTGGT CATCCGTATT GAGGATGATG GCGTTGGCTT CCAAAATGCT  
 2940  
 5 GGTGATAGTA GTCAAAGTCA ACTCAAACGT GGGGGAGTTG GTCTTCAAAAA TGTCGATCAA  
 3000  
 CGGCTCAAAC TTCATTTGG AGCCAATTAC CAGATGAAGA TTGATTCTAC ACCCCAAAAA  
 3060  
 10 GGGACGAAAG TTGAAATATA TATAAATACA GTAGAAACTA GATAACTCCC AGTCAATTCT  
 3120  
 GGGAGTCTTA TGCCT  
 3135  
 15

## (2) INFORMATION FOR SEQ ID NO:4:

## 20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 554 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Val Ile Ser Ile Phe Leu Val Phe Leu Ile Leu Leu Ala Leu Val  
 1 5 10 15  
 Gly Thr Phe Tyr Tyr Gln Ser Ser Ser Ser Ala Ile Glu Ala Thr Ile  
 35 20 25 30  
 Glu Gly Asn Ser Gln Thr Thr Ile Ser Gln Thr Ser His Phe Ile Gln  
 35 40 45  
 Ser Tyr Ile Lys Lys Leu Glu Thr Thr Ser Thr Gly Ile Thr Gln Gln  
 40 50 55 60  
 Thr Asp Val Leu Ala Tyr Ala Glu Asn Pro Ser Gln Asp Lys Val Glu  
 65 70 75 80  
 Gly Ile Arg Asp Leu Phe Leu Thr Ile Leu Lys Ser Asp Lys Asp Leu  
 45 85 90 95  
 Lys Thr Val Val Leu Val Thr Lys Ser Gly Gln Val Ile Ser Thr Asp  
 100 105 110  
 Asp Ser Val Gln Met Lys Thr Ser Ser Asp Met Met Ala Glu Asp Trp  
 50 115 120 125  
 Tyr Gln Lys Ala Ile His Gln Gly Val Met Pro Val Leu Thr Pro Ala  
 130 135 140

Arg Lys Ser Asp Ser Gln Trp Val Ile Ser Val Thr Gln Glu Leu Val  
 145 150 155 160  
 5 Asp Ala Lys Gly Ala Asn Leu Gly Val Leu Arg Leu Asp Ile Ser Tyr  
 165 170 175  
 Glu Thr Leu Glu Ala Tyr Leu Asn Gln Leu Gln Leu Gly Gln Gln Gly  
 180 185 190  
 10 Phe Ala Phe Ile Ile Asn Glu Asn His Glu Phe Val Tyr His Pro Gln  
 195 200 205  
 His Thr Val Tyr Ser Ser Ser Lys Met Glu Ala Met Lys Pro Tyr  
 210 215 220  
 15 Ile Glu Thr Gly Gln Gly Tyr Thr Pro Gly His Lys Ser Tyr Val Ser  
 225 230 235 240  
 Gln Glu Lys Ile Ala Gly Thr Asp Trp Thr Val Leu Gly Val Ser Ser  
 20 245 250 255  
 Leu Glu Lys Leu Asp Gln Val Arg Ser Gln Leu Leu Trp Thr Leu Leu  
 260 265 270  
 25 Gly Ala Ser Val Thr Ser Leu Leu Val Cys Leu Cys Leu Val Trp Phe  
 275 280 285  
 Ser Leu Lys Arg Trp Ile Ala Pro Leu Lys Asp Leu Arg Glu Thr Met  
 290 295 300  
 30 Leu Glu Ile Ala Ser Gly Ala Gln Asn Leu Arg Ala Lys Glu Val Gly  
 305 310 315 320  
 Ala Tyr Glu Leu Arg Glu Val Thr Arg Gln Phe Asn Ala Met Leu Asp  
 325 330 335  
 35 Gln Ile Asp Gln Leu Met Val Ala Ile Arg Ser Gln Gly Glu Thr Thr  
 340 345 350  
 Arg Gln Tyr Gln Leu Gln Ala Leu Ser Ser Gln Ile Asn Pro His Phe  
 355 360 365  
 40 Leu Tyr Asn Thr Leu Asp Thr Ile Ile Trp Met Ala Glu Phe His Asp  
 370 375 380  
 Ser Gln Arg Val Val Gln Val Thr Lys Ser Leu Ala Thr Tyr Phe Arg  
 385 390 395 400  
 45 Leu Ala Leu Asn Gln Gly Lys Asp Leu Ile Cys Leu Ser Asp Glu Ile  
 405 410 415  
 Asn His Val Arg Gln Tyr Leu Phe Ile Gln Lys Gln Arg Tyr Gly Asp  
 420 425 430  
 50 Lys Leu Glu Tyr Glu Ile Asn Glu Asn Val Ala Phe Asp Asn Leu Val  
 435 440 445  
 Leu Pro Lys Leu Val Leu Gln Pro Leu Val Glu Asn Ala Leu Tyr His  
 450 455 460

Gly Ile Lys Glu Lys Glu Gly Gln Gly His Ile Lys Leu Ser Val Gln  
 465 470 475 480  
 5 Lys Gln Asp Ser Gly Leu Val Ile Arg Ile Glu Asp Asp Gly Val Gly  
 485 490 495  
 Phe Gln Asn Ala Gly Asp Ser Ser Gln Ser Gln Leu Lys Arg Gly Gly  
 500 505 510  
 10 Val Gly Leu Gln Asn Val Asp Gln Arg Leu Lys Leu His Phe Gly Ala  
 515 520 525  
 Asn Tyr Gln Met Lys Ile Asp Ser Thr Pro Gln Lys Gly Thr Lys Val  
 15 530 535 540  
 Glu Ile Tyr Ile Asn Thr Val Glu Thr Arg  
 545 550

20 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 25 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

35 ATGACCTACA CAATCTTAAT CGTAG  
 25

40 (2) INFORMATION FOR SEQ ID NO:6:

45 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TCGGTCTTCT CCCTTCTTAA ACTG

## Claims

1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
  - 5 (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
  - (b) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the response regulator gene contained in the *Streptococcus pneumoniae* of the deposited strain;
  - 10 (c) a polynucleotide encoding a polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2;
  - (d) a polynucleotide which is complementary to the polynucleotide of (a), (b) or (c); and
  - (e) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a), (b) or (c).
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
- 15 3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 2 comprising the nucleic acid sequence set forth in SEQ ID NO:1.
- 20 5. The polynucleotide of Claim 2 comprising nucleotide 680 to 1414 set forth in SEQ ID NO:1.
6. The polynucleotide of Claim 2 which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
- 25 7. A vector comprising the polynucleotide of Claim 1.
8. A host cell comprising the vector of Claim 7.
9. A process for producing a polypeptide comprising: expressing from the host cell of Claim 8 a polypeptide encoded by said DNA.
- 30 10. A process for producing a response regulator polypeptide or fragment comprising culturing a host of claim 8 under conditions sufficient for the production of said polypeptide or fragment.
11. A polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2.
- 35 12. A polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.
13. An antibody against the polypeptide of claim 11.
- 40 14. An antagonist which inhibits the activity or expression of the polypeptide of claim 11.
15. A method for the treatment of an individual in need of response regulator polypeptide comprising: administering to the individual a therapeutically effective amount of the polypeptide of claim 11.
- 45 16. A method for the treatment of an individual having need to inhibit response regulator polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of Claim 14.
17. A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an individual comprising:
  - 50 (a) determining a nucleic acid sequence encoding said polypeptide, and/or
  - (b) analyzing for the presence or amount of said polypeptide in a sample derived from the individual.
- 55 18. A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 comprising:
 

contacting a composition comprising the polypeptide with the compound to be screened under conditions to

5 permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the polypeptide with the compound;  
and determining whether the compound interacts with and activates or inhibits an activity of the polypeptide by detecting the presence or absence of a signal generated from the interaction of the compound with the polypeptide.

10 19. A method for inducing an immunological response in a mammal which comprises inoculating the mammal with response regulator polypeptide of claim 11, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said animal from disease.

15 20. A method of inducing immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of response regulator polypeptide of claim 11, or fragment or a variant thereof, for expressing said response regulator polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease.

20

25

30

35

40

45

50

55